NasdaqGS:QUREBiotechs
uniQure (QURE) Rebound Puts AMT 130 Valuation Debate Back In Focus
uniQure (QURE) has drawn fresh attention after a strong rebound in its share price over the past month and past 3 months, prompting investors to reassess the gene therapy company’s risk and return trade off.
See our latest analysis for uniQure.
Over the past year, uniQure’s 182.47% total shareholder return and 285.92% three year total shareholder return contrast with a recent 3.59% one day share price decline. This suggests strong longer term momentum alongside short term volatility as...